Equity Profile

MDGL

Madrigal Pharmaceuticals, Inc.

Health CareBiotechnology$11.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical indicator of the company's profitability and financial health.

$-1.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$401M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious liver diseases. With a market cap of $12 billion, its work is particularly relevant as the healthcare sector increasingly prioritizes advanced treatments for chronic conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

In Q1 2026, Madrigal reported an EPS of $-3.25, beating expectations by nearly 10%. The stock reacted positively, gaining 7.42% the following day.

Management Promises & Guidance

Management committed to advancing their clinical trials.
They indicated ongoing investment in research and development.
They expressed confidence in their pipeline of therapies.

Expectations

Wall Street Expectations

Analysts expect Madrigal to report a loss but anticipate a modest revenue increase. The consensus is cautiously optimistic given the company's recent performance.

Bull Case

If Madrigal can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its therapies, leading to a significant stock rally.

Bear Case

Conversely, if the company fails to meet revenue targets or reports a larger loss than expected, it may lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

$-1.12

Earnings per share (EPS) is a critical indicator of the company's profitability and financial health.

Revenue

$401M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Madrigal achieve revenue of at least $401M this quarter?

Meeting or exceeding this revenue target will indicate strong market demand for their products and could boost investor confidence.

How will the company address its expected EPS loss of $-1.12?

Understanding the reasons behind the anticipated loss and management's strategies to improve profitability will be crucial for investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Madrigal's potential for revenue growth due to its innovative pipeline, which could outperform current projections.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

Recent positive clinical trial results may not yet be fully factored into revenue expectations.

The options market indicates a high level of uncertainty, which could imply that analysts are overly cautious.

Key Risk

If revenue comes in significantly above $401M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Madrigal's recent advancements in clinical trials will translate into improved financial performance.

Bull Confirmed If

Achieving an EPS loss of $-1.00 or better, combined with revenue exceeding $401M.

Bear Confirmed If

An EPS loss greater than $-1.12 and revenue falling below $385M.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations, history suggests a potential stock increase of around 6.18%, confirming positive market sentiment.

In-Line / Cautious

An in-line report may lead to muted reactions as investors await further guidance from management.

Miss

If the company misses expectations, history suggests a decline of about 1.64%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and timelines.
2Details on revenue drivers and product demand.
3Management's outlook on future profitability.
4Responses to competitive pressures in the biotechnology sector.
5Insights into cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a critical indicator of the company's profitability and financial health.

$-1.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$401M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

In Q1 2026, Madrigal reported an EPS of $-3.25, beating expectations by nearly 10%. The stock reacted positively, gaining 7.42% the following day.

Management Promises & Guidance

Management committed to advancing their clinical trials.
They indicated ongoing investment in research and development.
They expressed confidence in their pipeline of therapies.

Expectations

Wall Street Expectations

Analysts expect Madrigal to report a loss but anticipate a modest revenue increase. The consensus is cautiously optimistic given the company's recent performance.

Bull Case

If Madrigal can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its therapies, leading to a significant stock rally.

Bear Case

Conversely, if the company fails to meet revenue targets or reports a larger loss than expected, it may lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

$-1.12

Earnings per share (EPS) is a critical indicator of the company's profitability and financial health.

Revenue

$401M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Madrigal achieve revenue of at least $401M this quarter?

Meeting or exceeding this revenue target will indicate strong market demand for their products and could boost investor confidence.

How will the company address its expected EPS loss of $-1.12?

Understanding the reasons behind the anticipated loss and management's strategies to improve profitability will be crucial for investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Madrigal's potential for revenue growth due to its innovative pipeline, which could outperform current projections.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

Recent positive clinical trial results may not yet be fully factored into revenue expectations.

The options market indicates a high level of uncertainty, which could imply that analysts are overly cautious.

Key Risk

If revenue comes in significantly above $401M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Madrigal's recent advancements in clinical trials will translate into improved financial performance.

Bull Confirmed If

Achieving an EPS loss of $-1.00 or better, combined with revenue exceeding $401M.

Bear Confirmed If

An EPS loss greater than $-1.12 and revenue falling below $385M.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations, history suggests a potential stock increase of around 6.18%, confirming positive market sentiment.

In-Line / Cautious

An in-line report may lead to muted reactions as investors await further guidance from management.

Miss

If the company misses expectations, history suggests a decline of about 1.64%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and timelines.
2Details on revenue drivers and product demand.
3Management's outlook on future profitability.
4Responses to competitive pressures in the biotechnology sector.
5Insights into cost management strategies.